Savara Inc.
SVRASavara Inc. (SVRA) is a clinical-stage pharmaceutical company focused on developing therapies for rare and ultra-rare respiratory diseases. The company's pipeline includes inhaled treatments aimed at conditions such as alveolar phospholipoproteinosis (PAP) and other rare pulmonary disorders. Savara's approach involves leveraging innovative drug delivery methods to address unmet medical needs in these specialized areas.
Company News
Savara Inc. announced that Chief Financial and Administrative Officer Dave Lowrance is stepping down effective July 15, 2026, for health-related reasons. His responsibilities will be split, with Chief Operating Officer Robert Lutz assuming the CFO role while administrative duties are distributed among senior leadership. Lutz brings over two decad...
Savara Inc. (NASDAQ: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced that its management team will participate in one-on-one meetings and a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 3rd. The company's lead program, MOLBREEVI, is a recombinant human GM-CSF in Phase 3 ...
Savara Inc., a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced that its management team will participate in a fireside chat at the H.C. Wainwright & Co. 4th Annual BioConnect Investor Conference on May 19th at 10:00am ET in New York. The company's lead program, MOLBREEVI, is a recombinant human GM-CSF in P...
Savara Inc. announced it received a Day 74 Letter from the FDA indicating no Advisory Committee meeting is planned for MOLBREEVI's Biologics License Application, with a PDUFA target action date of August 22, 2026. The company has submitted a Marketing Authorization Application to the European Medicines Agency and remains on track to submit to the...
Savara Inc. (NASDAQ: SVRA), a clinical stage biopharmaceutical company, announced that its management team will participate in a fireside chat at the 2026 Citizens Life Sciences Conference on March 11th in Miami, FL. The company is focused on rare respiratory diseases with its lead program MOLBREEVI, a recombinant human GM-CSF in Phase 3 developm...
